SFF
Our president of manufacturing services, Kjell Johansson, discusses the key challenges that CDMOs face during aseptic manufacturing and the trends impacting the industry with Contract Pharma.
Contract Pharma, 20th April 2017
Highly potent oncology drugs and injectables are driving the demand for CDMOs to meet the stringent regulatory requirements surrounding the manufacture of sterile products.
As the need to manufacture more challenging drugs for smaller patient populations increases so too does the demand for aseptic manufacturing.